Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04539886 · ClinicalTrials.gov registry record · NA
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions
A NA study, sponsored by Pulse Biosciences.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT04539886: Completed NA study, sponsored by Pulse Biosciences.
NCT04539886 is a NA study that has completed, run by Pulse Biosciences. The registered enrollment target is 60 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04539886, a NA study, has completed, sponsored by Pulse Biosciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
This study is designed as a multi-center, single-blinded, prospective, randomized, study to compare the safety and effectiveness of the CellFX System to the comparator group, Electrodessication for the treatment of SH lesions in healthy adult subjects.
Primary Outcome
Percentage of SH Lesions with Improvement as Assessed by Blinded Investigator During Live Assessments based on Global Aesthetic Improvement Scale (GAIS). The Global Aesthetic Improvement Scale ranges from 1=Very Much Improved or Excellent Corrective Result to 5=Worsened Appearance Compared with Original Condition. The primary effectiveness endpoint of improvement at 60-days post-last treatment as assessed "live" by the blinded site investigator using the 5-point GAIS
Interventions
- DEVICE CellFX System
- DEVICE Intralesional Electrodesiccation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2020-09-28 |
| Est. Completion | 2021-11-18 |
| Phase | NA |
What the finished NCT04539886 record still lists
NCT04539886 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which CellFX System is the first listed.
NCT04539886 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04539886 about?
NCT04539886 is a clinical study titled "Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) Lesions". This study is designed as a multi-center, single-blinded, prospective, randomized, study to compare the safety and effectiveness of the CellFX System to the comparator group, Electrodessication for the treatment of SH lesions in healthy adult subjects.
What is the current status of trial NCT04539886?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants. The study started on 2020-09-28. Estimated completion is 2021-11-18.
What interventions are being tested in trial NCT04539886?
The interventions under investigation include: CellFX System (DEVICE), Intralesional Electrodesiccation (DEVICE).
Who is sponsoring clinical trial NCT04539886?
This trial is sponsored by Pulse Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04539886's enrollment target sits among peer trials
60 1164th of 2000 higher than 745 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI